论文部分内容阅读
目的观察重组人血小板活化因子乙酰水解酶(rPAF-AH)对大鼠脑梗死的治疗作用。方法 Wistar大鼠80只,采用分层随机法分为4组,空白组,模型组,rPAF AH组和银杏叶组,每组20只。后3组大鼠采用慢性动脉粥样硬化结合线栓法制成大鼠大脑中动脉闭塞脑梗死模型,观测各组大鼠神经行为学、脑梗死指数、血小板聚集率和血小板黏附率及5、15、30和60 min各时间点局部脑血流量(rCBF)变化,并进行比较。结果与空白组比较,模型组大鼠的神经行为学评分、脑梗死指数、血小板聚集率和血小板黏附率均明显升高(P<0.01);与模型组比较,除外银杏叶组血小板聚集率,rPAF-AH组和银杏叶组大鼠的神经行为学评分、脑梗死指数、血小板聚集率和血小板黏附率均明显降低(P<0.05),rPAF-AH组较银杏叶组血小板聚集率下降明显(P<0.05)。与空白组比较,模型组大鼠各时间点rCBF明显下降;与模型组比较,rCBF-AH组大鼠给药后各时间点,银杏叶组30和60 min时,rCBF不同程度升高(P<0.05)。结论 rPAF-AH对大鼠脑梗死具有明显的疗效,是一种值得期待的治疗脑梗死的生物医药制剂。
Objective To observe the therapeutic effect of recombinant human platelet activating factor acetylhydrolase (rPAF-AH) on cerebral infarction in rats. Methods Eighty Wistar rats were randomly divided into 4 groups: blank group, model group, rPAF AH group and Ginkgo biloba group, with 20 rats in each group. The rats in the latter three groups were made into model of middle cerebral artery occlusion cerebral infarction by chronic atherosclerosis combined with suture method. The neurobehavioral indexes, cerebral infarction index, platelet aggregation rate, platelet adhesion rate and 5,15 , 30 min and 60 min at each time point changes in regional cerebral blood flow (rCBF), and compared. Results Compared with the blank group, the neurobehavioral score, cerebral infarction index, platelet aggregation rate and platelet adhesion rate in the model group were significantly increased (P <0.01). Compared with the model group, except the Ginkgo biloba group platelet aggregation rate, The neurobehavioral score, cerebral infarction index, platelet aggregation rate and platelet adhesion rate in rPAF-AH group and ginkgo leaf group were significantly decreased (P <0.05), and the platelet aggregation rate in rPAF-AH group was significantly lower than that in ginkgo leaf group P <0.05). Compared with the blank group, the rCBF of model rats decreased significantly at each time point. Compared with model group, rCBF increased at different time points in rats of rCBF-AH group and at 30 and 60 min of Ginkgo biloba group (P <0.05). Conclusion rPAF-AH has obvious curative effect on cerebral infarction in rats and is a promising biomedical agent for the treatment of cerebral infarction.